How can we ensure public return on public investment?: Access to medicines in the context of COVID19
Date(s) - 23/06/2020
11:00 CEST - 12:00 CEST
Categories No Categories
Health Action International (HAI) and Universities Allied for Essential Medicines (UAEM) Europe will host an online discussion on the need for new ways to harness innovation and promote access to medicines within and beyond the current market oriented, patent-centred model.
In the context of the challenges exacerbated by the COVID-19 pandemic, we will look at the latest developments in Europe, with specific focus on Germany, while considering the resources included in HAI’s publication “Guidelines for Socially Responsible Management of Innovation”.
For the last decade, Germany has witnessed an animated debate between academics, advocates and policy makers around how best to articulate public-generated knowledge and industrial policies, including the development and manufacturing of medicines. This discussion is gaining new traction with the occurrence of shortages of medicines and the need to respond to a health crisis.
As a leading player in the European Union (EU) health policy debate and as the country about to take up the Presidency of the European Council, Germany can make a strong case for a socially responsible response to COVID-19, as well as to other obstacles affecting access to medicines.
This discussion will bring together a diverse audience to exchange ideas on the importance of access to innovation in Germany, and the wider EU, grounding the debate in the responsibility of government, public authorities, universities and public research institutions to ensure public return on public investment.
Please find more information and register at bit.ly/publicreturn_corona.
Please note: The event will be held in German and English. Unfortunately, we can’t provide translation.